Enhancing the QUAlity and Transparency Of health Research
Use your browser's Back button to return to your search results
|Reporting guideline provided for?
(i.e. exactly what the authors state in the paper)
|Reporting of HIV drug resistance (HIVDR) prevalence or incidence studies.|
|Full bibliographic reference||Mbuagbaw L, Garcia C, Brenner B, Cecchini D, Chakroun M, Djiadeu P, Holguin A, Mor O, Parkin N, Santoro MM, Ávila-Ríos S, Fokam J, Phillips A, Shafer RW, Jordan MR. Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use. Lancet HIV. 2023:S2352-3018(23)00173-X.|
(full-text if available)
|The checklists are available from the CEDRIC-HIV website.|
|Availability in additional languages||Translations of the checklist are avilable in French, Portuguese, Chinese, Spanish and Italian.|
|Reporting guideline website URL||http://cedric-hiv.com/|
|Reporting guideline acronym||CEDRIC-HIV|
|Study design||Clinical trials, Experimental studies, Observational studies|
|Clinical area||Infectious diseases, Public health|
|Applies to the whole report or to individual sections of the report?||Whole report|
|Record last updated on||September 28, 2023|
Some reporting guidelines are also available in languages other than English. Find out more in our Translations section.